Desmopressin: A nontransfusional form of treatment for congenital and acquired bleeding disorders

Research output: Contribution to journalArticle

230 Citations (Scopus)

Abstract

Desmopressin (1-deamino-8-D-arginine vasopressin, abbreviated DDAVP) is a synthetic analogue of the antidiuretic hormone L-arginine vasopressin. Because it can rise circulating levels of factor VIII coagulant activity (FVIII) and von Willebrand factor and shorten the prolonged bleeding time, DDAVP is established as a nontransfusional form of treatment for mild and moderate hemophilia and von Willebrand disease. Recently, DDAVP has also been purported to be useful for shortening the prolonged skin bleeding times that occur with uremia, cirrhosis, and platelet dysfunctions of various etiologies. Finally, there is evidence from controlled clinical trials that DDAVP can reduce blood loss and transfusion requirements for hemostatically normal individuals undergoing spinal fusion surgery and for patients undergoing cardiopulmonary bypass surgery. The purpose of this report is to review the therapeutic applications of DDAVP in congenital and acquired bleeding disorders and to discuss areas in which further basic and clinical research is needed.

Original languageEnglish
Pages (from-to)1449-1455
Number of pages7
JournalBlood
Volume72
Issue number5
Publication statusPublished - 1988

Fingerprint

Deamino Arginine Vasopressin
Hemorrhage
Bleeding Time
Surgery
Therapeutics
von Willebrand Diseases
Coagulants
Spinal Fusion
Arginine Vasopressin
Uremia
Controlled Clinical Trials
Factor VIII
Hemophilia A
von Willebrand Factor
Platelets
Cardiopulmonary Bypass
Vasopressins
Blood Transfusion
Arginine
Skin

ASJC Scopus subject areas

  • Hematology

Cite this

Desmopressin : A nontransfusional form of treatment for congenital and acquired bleeding disorders. / Mannucci, P. M.

In: Blood, Vol. 72, No. 5, 1988, p. 1449-1455.

Research output: Contribution to journalArticle

@article{5365e6aa8e5f4c08a326ca2600de8b25,
title = "Desmopressin: A nontransfusional form of treatment for congenital and acquired bleeding disorders",
abstract = "Desmopressin (1-deamino-8-D-arginine vasopressin, abbreviated DDAVP) is a synthetic analogue of the antidiuretic hormone L-arginine vasopressin. Because it can rise circulating levels of factor VIII coagulant activity (FVIII) and von Willebrand factor and shorten the prolonged bleeding time, DDAVP is established as a nontransfusional form of treatment for mild and moderate hemophilia and von Willebrand disease. Recently, DDAVP has also been purported to be useful for shortening the prolonged skin bleeding times that occur with uremia, cirrhosis, and platelet dysfunctions of various etiologies. Finally, there is evidence from controlled clinical trials that DDAVP can reduce blood loss and transfusion requirements for hemostatically normal individuals undergoing spinal fusion surgery and for patients undergoing cardiopulmonary bypass surgery. The purpose of this report is to review the therapeutic applications of DDAVP in congenital and acquired bleeding disorders and to discuss areas in which further basic and clinical research is needed.",
author = "Mannucci, {P. M.}",
year = "1988",
language = "English",
volume = "72",
pages = "1449--1455",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Desmopressin

T2 - A nontransfusional form of treatment for congenital and acquired bleeding disorders

AU - Mannucci, P. M.

PY - 1988

Y1 - 1988

N2 - Desmopressin (1-deamino-8-D-arginine vasopressin, abbreviated DDAVP) is a synthetic analogue of the antidiuretic hormone L-arginine vasopressin. Because it can rise circulating levels of factor VIII coagulant activity (FVIII) and von Willebrand factor and shorten the prolonged bleeding time, DDAVP is established as a nontransfusional form of treatment for mild and moderate hemophilia and von Willebrand disease. Recently, DDAVP has also been purported to be useful for shortening the prolonged skin bleeding times that occur with uremia, cirrhosis, and platelet dysfunctions of various etiologies. Finally, there is evidence from controlled clinical trials that DDAVP can reduce blood loss and transfusion requirements for hemostatically normal individuals undergoing spinal fusion surgery and for patients undergoing cardiopulmonary bypass surgery. The purpose of this report is to review the therapeutic applications of DDAVP in congenital and acquired bleeding disorders and to discuss areas in which further basic and clinical research is needed.

AB - Desmopressin (1-deamino-8-D-arginine vasopressin, abbreviated DDAVP) is a synthetic analogue of the antidiuretic hormone L-arginine vasopressin. Because it can rise circulating levels of factor VIII coagulant activity (FVIII) and von Willebrand factor and shorten the prolonged bleeding time, DDAVP is established as a nontransfusional form of treatment for mild and moderate hemophilia and von Willebrand disease. Recently, DDAVP has also been purported to be useful for shortening the prolonged skin bleeding times that occur with uremia, cirrhosis, and platelet dysfunctions of various etiologies. Finally, there is evidence from controlled clinical trials that DDAVP can reduce blood loss and transfusion requirements for hemostatically normal individuals undergoing spinal fusion surgery and for patients undergoing cardiopulmonary bypass surgery. The purpose of this report is to review the therapeutic applications of DDAVP in congenital and acquired bleeding disorders and to discuss areas in which further basic and clinical research is needed.

UR - http://www.scopus.com/inward/record.url?scp=0023757497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023757497&partnerID=8YFLogxK

M3 - Article

C2 - 3052622

AN - SCOPUS:0023757497

VL - 72

SP - 1449

EP - 1455

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -